A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

(2022) Hussein A. Tawbi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion

(2021) Nicole E. Scharping et al.   NATURE IMMUNOLOGY

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours

(2021) Roberta Zappasodi et al.   NATURE

Metabolic support of tumour-infiltrating regulatory T cells by lactic acid

(2021) McLane J. Watson et al.   NATURE

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

(2021) E. A. Rozeman et al.   NATURE MEDICINE

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

(2021) Alexander M. Menzies et al.   NATURE MEDICINE

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

(2021) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Emerging concepts in PD-1 checkpoint biology

(2021) Kristen E. Pauken et al.   SEMINARS IN IMMUNOLOGY

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma

(2021) R.V. Rawson et al.   ANNALS OF ONCOLOGY

LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

(2021) J.J. Luke et al.   ANNALS OF ONCOLOGY

Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

(2021) Georgina V. Long et al.   CLINICAL CANCER RESEARCH

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.

(2021) Rodabe Navroze Amaria et al.   JOURNAL OF CLINICAL ONCOLOGY

Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma

(2021) Giacomo Oliveira et al.   NATURE

Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy

(2021) Simon Eschweiler et al.   NATURE IMMUNOLOGY

Recent Advances in the Treatment of Melanoma

(2021) Brendan D. Curti et al.   NEW ENGLAND JOURNAL OF MEDICINE

LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade

(2021) Ronglai Shen et al.   Science Translational Medicine

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

(2021) Julie R Brahmer et al.   Journal for ImmunoTherapy of Cancer

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

(2021) Jedd D. Wolchok et al.   JOURNAL OF CLINICAL ONCOLOGY

655 Landscape of helper and regulatory CD4+ T cells in melanoma

(2021) Giacomo Oliveira et al.   Journal for ImmunoTherapy of Cancer

B cells are associated with survival and immunotherapy response in sarcoma

(2020) Florent Petitprez et al.   NATURE

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

(2020) Rita Cabrita et al.   NATURE

B cells and tertiary lymphoid structures promote immunotherapy response

(2020) Beth A. Helmink et al.   NATURE

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

(2020) Haiping Wang et al.   NATURE IMMUNOLOGY

Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences

(2020) Brandon E. Cohen et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.

(2020) Christian U. Blank et al.   JOURNAL OF CLINICAL ONCOLOGY

Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy

(2020) Xiaoying Sun et al.   Frontiers in Oncology

Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding

(2020) Lawrence P. Andrews et al.   Science Immunology

Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors

(2020) Vid Leko et al.   CANCER CELL

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

(2020) Shogo Kumagai et al.   NATURE IMMUNOLOGY

Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype

(2020) Ashvin R. Jaiswal et al.   Cancer Immunology Research

LAG-3: from molecular functions to clinical applications

(2020) Takumi Maruhashi et al.   Journal for ImmunoTherapy of Cancer

Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

(2020) Sri Krishna et al.   SCIENCE

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases

(2019) Grant M. Fischer et al.   Cancer Discovery

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

(2019) Takahiro Kamada et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors

(2019) Danny N. Khalil et al.   JOURNAL OF CLINICAL INVESTIGATION

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

(2019) Rodabe N Amaria et al.   LANCET ONCOLOGY

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

(2019) Alexander M.M. Eggermont et al.   EUROPEAN JOURNAL OF CANCER

Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment

(2019) Monica Marzagalli et al.   SEMINARS IN CANCER BIOLOGY

Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells

(2019) Marco Tucci et al.   Frontiers in Oncology

CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions

(2018) Masao Hashimoto et al.   Annual Review of Medicine

Non-conventional Inhibitory CD4 + Foxp3 − PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity

(2018) Roberta Zappasodi et al.   CANCER CELL

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

(2018) Roberta Zappasodi et al.   CANCER CELL

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

(2018) Frederick Arce Vargas et al.   CANCER CELL

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

(2018) Jan P. Böttcher et al.   CELL

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

(2018) Tina Cascone et al.   Cell Metabolism

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

(2018) Muhammad Zubair Afzal et al.   Journal for ImmunoTherapy of Cancer

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Strategies for Predicting Response to Checkpoint Inhibitors

(2018) Roberta Zappasodi et al.   Current Hematologic Malignancy Reports

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

(2018) Hanjie Li et al.   CELL

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

(2018) Paolo A. Ascierto et al.   JAMA Oncology

Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma

(2017) Sun Hye Kim et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

(2017) Samra Turajlic et al.   LANCET ONCOLOGY

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

(2016) Almut Brand et al.   Cell Metabolism

Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome

(2016) Kanika Garg et al.   HUMAN PATHOLOGY

CD28 Costimulation: From Mechanism to Therapy

(2016) Jonathan H. Esensten et al.   IMMUNITY

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

(2016) Stephanie L. Goff et al.   JOURNAL OF CLINICAL ONCOLOGY

Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma

(2016) Elizabeth Ann L. Enninga et al.   MELANOMA RESEARCH

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens

(2016) T. D. Prickett et al.   Cancer Immunology Research

Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses

(2015) Nikhil S. Joshi et al.   IMMUNITY

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunogenicity of somatic mutations in human gastrointestinal cancers

(2015) E. Tran et al.   SCIENCE

A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

(2015) B. M. Carreno et al.   SCIENCE

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene

(2015) Arnaldur Hall et al.   Oncotarget

A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma

(2014) Miguel Martinez-Rodriguez et al.   HISTOPATHOLOGY

Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection

(2014) Alison Crawford et al.   IMMUNITY

Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4

(2014) James Badger Wing et al.   IMMUNITY

The Coinhibitory Receptor CTLA-4 Controls B Cell Responses by Modulating T Follicular Helper, T Follicular Regulatory, and T Regulatory Cells

(2014) Peter T. Sage et al.   IMMUNITY

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

(2014) Carsten Linnemann et al.   NATURE MEDICINE

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

(2014) Ahmad A. Tarhini et al.   PLoS One

Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF

(2013) Rizwan Haq et al.   CANCER CELL

MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells

(2013) Maria Falck Miniotis et al.   CANCER RESEARCH

Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study

(2013) Nancy E. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression

(2013) Y.-C. Lu et al.   JOURNAL OF IMMUNOLOGY

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy

(2013) D. Ng Tang et al.   Cancer Immunology Research

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis

(2013) Wanting Liu et al.   PeerJ

Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases

(2012) Arcadi Cipponi et al.   CANCER RESEARCH

Dissection of T-cell Antigen Specificity in Human Melanoma

(2012) R. S. Andersen et al.   CANCER RESEARCH

Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma

(2012) G. Erdag et al.   CANCER RESEARCH

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

(2012) L. G. Radvanyi et al.   CLINICAL CANCER RESEARCH

Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma

(2012) Farhad Azimi et al.   JOURNAL OF CLINICAL ONCOLOGY

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Melanoma-infiltrating dendritic cells

(2012) Jared S. Klarquist et al.   OncoImmunology

TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients

(2012) Pia Kvistborg et al.   OncoImmunology

NRAS mutation status is an independent prognostic factor in metastatic melanoma

(2011) John A. Jakob et al.   CANCER

Prognostic impact of B-cell density in cutaneous melanoma

(2011) Andrea Ladányi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy

(2011) Orit Itzhaki et al.   JOURNAL OF IMMUNOTHERAPY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies

(2011) Amy E. Gilbert et al.   PLoS One

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Langerhans Cells Are Required for UVR-Induced Immunosuppression

(2010) Agatha Schwarz et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma

(2009) W. K. Nevala et al.   CLINICAL CANCER RESEARCH

Epidermal Langerhans Cells Are Not Required for UV-Induced Immunosuppression

(2009) L. Wang et al.   JOURNAL OF IMMUNOLOGY

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

(2008) B. Kavanagh et al.   BLOOD

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions

(2008) M. Ahmadzadeh et al.   BLOOD

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY